We then decided to test the therapeutic efficacy of 2-O-Bn-InsP5 in human tumour xenografts characterised by the activation of PI3K/Akt pathway and higher sensitivity to 2-O-Bn-InsP5 compared with InsP5. This evidence concerns the gene AKT1 and neoplasm.